Khosla Ventures Acquisition Co
Change company Symbol lookup
Select an option...
KVSA Khosla Ventures Acquisition Co
FPI Farmland Partners Inc
HNST Honest Company Inc
ONTF ON24 Inc
ATAI ATAI Life Sciences NV
FTS Fortis Inc
VLO Valero Energy Corp
BBLN+ Babylon Holdings Equity Warrants 21st Oct 2026 *W EXP 10/21/2026
NEGG Newegg Commerce Inc
LTRY Lottery.com Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Company profile

Khosla Ventures Acquisition Co. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on market opportunity with differentiated, proprietary technology. The Company has not commenced any operations and has not generated revenues.

Closing Price
$9.81
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.82
Day's Low
9.79
Volume
(Heavy Day)
Volume:
172,786

10-day average volume:
19,311
172,786

DEADLINE ALERT for APYX, VRCA, APPS, TDOC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

12:00 pm ET August 3, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NYSE:TDOC),(NASDAQ:APYX),(NasdaqGM:VRCA),(NASDAQ:APPS), EQNX::TICKER_END Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

Apyx Medical Corporation (NASDAQ: APYX)

Class Period: May 12, 2021 - March 11, 2022

Lead Plaintiff Deadline: August 5, 2022

The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose: (1) that a significant number of Apyx's Advanced Energy products were used for off-label indications; (2) that such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events; (3) that, as a result, the Company was reasonably likely to incur regulatory scrutiny; (4) that, as a result of the foregoing, the Company's financial results would be adversely impacted; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA)

Class Period: May 28, 2021 - May 24, 2022

Lead Plaintiff Deadline: August 5, 2022

The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose: (1) that there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced bulk solution for VP-102; (2) that these deficiencies were not remediated when Verrica resubmitted its NDA for VP-102 for molluscum; (3) that the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Digital Turbine, Inc. (NASDAQ: APPS)

Class Period: February 26, 2021 - May 31, 2022

Lead Plaintiff Deadline: August 5, 2022

The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company's recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines; (2) that, as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis; (3) that the Company's internal control over financial reporting as to revenue recognition was deficient; and (4) that, as a result of the foregoing, the Company's net revenues was overstated throughout fiscal 2022; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Teladoc Health, Inc. (NYSE: TDOC)

Class Period: October 28, 2021 - April 27, 2022

Lead Plaintiff Deadline: August 5, 2022

The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) increased competition, among other factors, was negatively impacting Teladoc's BetterHelp and chronic care businesses; (2) accordingly, the growth of those businesses was less sustainable than Defendants had led investors to believe; (3) as a result, Teladoc's revenue and adjusted EBITDA projections for FY 2022 were unrealistic; (4) as a result of all the foregoing, Teladoc would be forced to recognize a significant non-cash goodwill impairment charge; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

888-638-4847

howardsmith@howardsmithlaw.com

www.howardsmithlaw.com

https://ml.globenewswire.com/media/NDQwODNkOWEtMDgyYy00Y2FmLTk4OTEtNTI3NTU5NWE3YmFhLTEwMzIyOTk=/tiny/Law-Offices-of-Howard-G-Smith.png

https://ml.globenewswire.com/media/NDQwODNkOWEtMDgyYy00Y2FmLTk4OTEtNTI3NTU5NWE3YmFhLTEwMzIyOTk=/tiny/Law-Offices-of-Howard-G-Smith.png

comtex tracking

COMTEX_411508461/2010/2022-08-03T12:00:01

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.